4cni
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
<StructureSection load='4cni' size='340' side='right' caption='[[4cni]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='4cni' size='340' side='right' caption='[[4cni]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4cni]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CNI OCA]. <br> | + | <table><tr><td colspan='2'>[[4cni]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CNI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CNI FirstGlance]. <br> |
| - | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TAM:TRIS(HYDROXYETHYL)AMINOMETHANE'>TAM</scene | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TAM:TRIS(HYDROXYETHYL)AMINOMETHANE'>TAM</scene></td></tr> |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4cni FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cni OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4cni RCSB], [http://www.ebi.ac.uk/pdbsum/4cni PDBsum]</span></td></tr> | |
| - | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4cni FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cni OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4cni RCSB], [http://www.ebi.ac.uk/pdbsum/4cni PDBsum]</span></td></tr> | + | </table> |
| - | <table> | + | |
== Disease == | == Disease == | ||
[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men. | [[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men. | ||
| Line 17: | Line 16: | ||
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.,Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A MAbs. 2014 May 1;6(3):773-81. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. PMID:24670876<ref>PMID:24670876</ref> | Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.,Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A MAbs. 2014 May 1;6(3):773-81. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. PMID:24670876<ref>PMID:24670876</ref> | ||
| - | From | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
</div> | </div> | ||
== References == | == References == | ||
| Line 23: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: Adams, R | + | [[Category: Human]] |
| - | [[Category: Baker, T | + | [[Category: Adams, R]] |
| - | [[Category: Bourne, T | + | [[Category: Baker, T]] |
| - | [[Category: Carrington, B | + | [[Category: Bourne, T]] |
| - | [[Category: Gelinas, R | + | [[Category: Carrington, B]] |
| - | [[Category: Henry, A | + | [[Category: Gelinas, R]] |
| - | [[Category: Lawson, A | + | [[Category: Henry, A]] |
| - | [[Category: Marshall, D | + | [[Category: Lawson, A]] |
| - | [[Category: Meier, C | + | [[Category: Marshall, D]] |
| - | [[Category: Neale, H | + | [[Category: Meier, C]] |
| - | [[Category: Popplewell, A | + | [[Category: Neale, H]] |
| - | [[Category: Rapecki, S | + | [[Category: Popplewell, A]] |
| - | [[Category: Shaw, S | + | [[Category: Rapecki, S]] |
| + | [[Category: Shaw, S]] | ||
[[Category: Cdp6038]] | [[Category: Cdp6038]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
[[Category: Interleukin 6]] | [[Category: Interleukin 6]] | ||
Revision as of 12:20, 4 January 2015
Crystal structure of the Fab portion of Olokizumab in complex with IL- 6
| |||||||||||
Categories: Human | Adams, R | Baker, T | Bourne, T | Carrington, B | Gelinas, R | Henry, A | Lawson, A | Marshall, D | Meier, C | Neale, H | Popplewell, A | Rapecki, S | Shaw, S | Cdp6038 | Immune system | Interleukin 6
